Advertisement
U.S. markets open in 7 hours 52 minutes
  • S&P Futures

    5,209.00
    -5.75 (-0.11%)
     
  • Dow Futures

    39,214.00
    -9.00 (-0.02%)
     
  • Nasdaq Futures

    18,186.75
    -44.75 (-0.25%)
     
  • Russell 2000 Futures

    2,047.80
    -2.00 (-0.10%)
     
  • Crude Oil

    82.57
    -0.15 (-0.18%)
     
  • Gold

    2,161.80
    -2.50 (-0.12%)
     
  • Silver

    25.26
    0.00 (0.00%)
     
  • EUR/USD

    1.0868
    -0.0008 (-0.08%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2713
    -0.0016 (-0.12%)
     
  • USD/JPY

    150.2700
    +1.1720 (+0.79%)
     
  • Bitcoin USD

    65,131.21
    -3,670.93 (-5.34%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,915.23
    +174.83 (+0.44%)
     

FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients

The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.

  • The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety and efficacy of lanifibranor combined with empagliflozin for non-cirrhotic NASH and Type 2 Diabetes (T2D).

  • LEGEND is expected to recruit a total of 63 non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with T2D.

  • Related: Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor.

  • The trial's primary efficacy endpoint is a change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment compared to baseline. Secondary endpoints include changes in liver enzymes, glycaemic and lipids parameters, inflammatory markers, and body fat composition.

  • The trial will be initiated in 1H of 2022, and top line results are expected for 2H of 2023.

  • Price Action: IVA shares closed 3.53% lower at $10.94 on Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement